[
  {
    "ts": "2025-06-30T12:42:03+00:00",
    "headline": "AbbVie to buy Capstan for up to $2.1 billion in immunology push",
    "summary": "(Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmune diseases.  The U.S. drugmaker has spent over $20 billion on acquisitions since 2023 as its flagship rheumatoid arthritis drug, Humira, lost patent protection.  Capstan develops CAR-T therapies, which use a patient's own immune cells, specifically T-cells, to fight diseases.",
    "url": "https://ca.finance.yahoo.com/news/abbvie-buy-capstan-therapeutics-2-124203939.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "799b4360-b9b1-3b64-81da-576164fb42a6",
      "content": {
        "id": "799b4360-b9b1-3b64-81da-576164fb42a6",
        "contentType": "STORY",
        "title": "AbbVie to buy Capstan for up to $2.1 billion in immunology push",
        "description": "",
        "summary": "(Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmune diseases.  The U.S. drugmaker has spent over $20 billion on acquisitions since 2023 as its flagship rheumatoid arthritis drug, Humira, lost patent protection.  Capstan develops CAR-T therapies, which use a patient's own immune cells, specifically T-cells, to fight diseases.",
        "pubDate": "2025-06-30T12:42:03Z",
        "displayTime": "2025-06-30T12:42:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/64791f5c88c25a6378e7e8c5cf536b00",
          "originalWidth": 800,
          "originalHeight": 457,
          "caption": "Test tubes are seen in front of a displayed Abbvie logo in this illustration",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.p56B2fZYqZlwn4_GgSj9A--~B/aD00NTc7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/64791f5c88c25a6378e7e8c5cf536b00.cf.webp",
              "width": 800,
              "height": 457,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K2kwmO57XsDx9XzuRqJbPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/64791f5c88c25a6378e7e8c5cf536b00.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://ca.finance.yahoo.com/news/abbvie-buy-capstan-therapeutics-2-124203939.html",
          "site": "finance",
          "region": "CA",
          "lang": "en-CA"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-buy-capstan-therapeutics-2-124203939.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-30T12:18:52+00:00",
    "headline": "RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market",
    "summary": "Investing.com -- RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for Biogen’s Leqembi to follow with significant commercial success.",
    "url": "https://finance.yahoo.com/news/rbc-says-lilly-could-blaze-121852519.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "6450367a-2eb7-3ed7-b777-e808bf4844b6",
      "content": {
        "id": "6450367a-2eb7-3ed7-b777-e808bf4844b6",
        "contentType": "STORY",
        "title": "RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market",
        "description": "",
        "summary": "Investing.com -- RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for Biogen’s Leqembi to follow with significant commercial success.",
        "pubDate": "2025-06-30T12:18:52Z",
        "displayTime": "2025-06-30T12:18:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rbc-says-lilly-could-blaze-121852519.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rbc-says-lilly-could-blaze-121852519.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-30T11:30:00+00:00",
    "headline": "Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy",
    "summary": "Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved for PMN, a rare immune-mediated disease affecting the kidneys with an estimated prevalence of ~36k patients in the U.S.1Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-medi",
    "url": "https://finance.yahoo.com/news/biogen-initiates-phase-3-study-113000563.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "aaca1ca9-2dbb-34fd-8739-3bb059e285e5",
      "content": {
        "id": "aaca1ca9-2dbb-34fd-8739-3bb059e285e5",
        "contentType": "STORY",
        "title": "Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy",
        "description": "",
        "summary": "Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved for PMN, a rare immune-mediated disease affecting the kidneys with an estimated prevalence of ~36k patients in the U.S.1Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-medi",
        "pubDate": "2025-06-30T11:30:00Z",
        "displayTime": "2025-06-30T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-initiates-phase-3-study-113000563.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-initiates-phase-3-study-113000563.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]